ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference Press release LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 04, 2018
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences Press release Key Updates September 19, 2017
ProQR to Present at Upcoming Scientific and Industry Conferences Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 07, 2023
ProQR Announces First Quarter 2023 Operating and Financial Results Press release Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas Stre May 16, 2023
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update Press release Key updates February 28, 2018